Literature DB >> 10482572

Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization.

C S Hung1, N Vander Heyden, L Ratner.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection of CD4(+) lymphocytes and macrophages involves interaction of the surface subunit of the envelope protein (gp120) with coreceptors. Isolates have been found with specific tropism for macrophages and/or T-cell lines, through the utilization of chemokine receptor CCR5 (R5) or CXCR4 (X4). The third hypervariable loop (V3 loop) of gp120 is the major determinant of tropism. Using chimeric envelopes between HXB2 (X4) and ADA (R5), we found that the C-terminal half of the V3 loop was sufficient to confer on HXB2 the ability to infect CCR5-expressing cells. A sequence motif was identified at positions 289 to 292 allowing 30% of wild-type levels of infection, whereas full activity was achieved with the conversion of Lys to Glu at position 287 in addition to the above motif. Moreover, V3 loops from either SF2 (X4R5) or SF162 (R5) also allowed infection of CCR5-expressing cells, supporting the importance of V3 loops in influencing CCR5 utilization. The effects of amino acid changes at position 287 on the level of infection via CCR5 showed that negatively charged residues (Glu and Asp) were optimal for efficient interaction whereas only bulky hydrophobic residues drastically reduced infection. In addition, sequences at the N terminus of the V3 loop independently modulated the level of infection via CCR5. This study also examined the susceptibility of chimeric envelopes to neutralization by anticoreceptor antibodies and suggested the presence of differential interaction between the chimeric envelopes and CCR5. These findings highlight the critical residues in the V3 loop that mediate HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482572      PMCID: PMC112839          DOI: 10.1128/JVI.73.10.8216-8226.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages.

Authors:  P Di Marzio; J Tse; N R Landau
Journal:  AIDS Res Hum Retroviruses       Date:  1998-01-20       Impact factor: 2.205

3.  HIV-1 V3 envelope sequences required for macrophage infection.

Authors:  T Henkel; P Westervelt; L Ratner
Journal:  AIDS       Date:  1995-04       Impact factor: 4.177

4.  CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage.

Authors:  L Xiao; S M Owen; I Goldman; A A Lal; J J deJong; J Goudsmit; R B Lal
Journal:  Virology       Date:  1998-01-05       Impact factor: 3.616

5.  Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo.

Authors:  P Westervelt; D B Trowbridge; L G Epstein; B M Blumberg; Y Li; B H Hahn; G M Shaw; R W Price; L Ratner
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

6.  Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications.

Authors:  W K Wang; T Dudek; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

7.  Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism.

Authors:  B Chesebro; K Wehrly; J Nishio; S Perryman
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

8.  Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.

Authors:  O Nussbaum; C C Broder; E A Berger
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  V3-independent determinants of macrophage tropism in a primary human immunodeficiency virus type 1 isolate.

Authors:  F M Kim; D L Kolson; J W Balliet; A Srinivasan; R G Collman
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

10.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Nature       Date:  1991-01-10       Impact factor: 49.962

View more
  59 in total

1.  The C-terminal proline-rich tail of human immunodeficiency virus type 2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells.

Authors:  H A Pancio; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.

Authors:  A L Hammond; J Lewis; J May; J Albert; P Balfe; J A McKeating
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 3.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; X Wu; W A O'Brien; L Ratner; J C Kappes; G M Shaw; E Hunter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy.

Authors:  Binshan Shi; Christina Kitchen; Barbara Weiser; Douglas Mayers; Brian Foley; Kimdar Kemal; Kathryn Anastos; Marc Suchard; Monica Parker; Cheryl Brunner; Harold Burger
Journal:  Virology       Date:  2010-05-08       Impact factor: 3.616

6.  Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

Authors:  B Labrosse; C Treboute; A Brelot; M Alizon
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.

Authors:  Mayla Hsu; Janet M Harouse; Agegnehu Gettie; Clarisa Buckner; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

8.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Authors:  Jacqueline D Reeves; Stephen A Gallo; Navid Ahmad; John L Miamidian; Phoebe E Harvey; Matthew Sharron; Stefan Pohlmann; Jeffrey N Sfakianos; Cynthia A Derdeyn; Robert Blumenthal; Eric Hunter; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

9.  Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding.

Authors:  Stéphane Basmaciogullari; Gregory J Babcock; Donald Van Ryk; Woj Wojtowicz; Joseph Sodroski
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

10.  Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1.

Authors:  Wei Huang; Arne Frantzell; Jonathan Toma; Signe Fransen; Jeannette M Whitcomb; Eric Stawiski; Christos J Petropoulos
Journal:  Virology       Date:  2010-11-10       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.